Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 7.

Journal Article

Brown, Jennifer R., Moslehi, Javid, O'Brien, Susan, Ghia, Paolo ORCID: 0000-0003-3750-7342, Hillmen, Peter, Cymbalista, Florence, Shanafelt, Tait D., Fraser, Graeme, Rule, Simon, Kipps, Thomas J., Coutre, Steven, Dilhuydy, Marie-Sarah, Cramer, Paula, Tedeschi, Alessandra, Jaeger, Ulrich, Dreyling, Martin, Byrd, John C., Howes, Angela, Todd, Michael, Vermeulen, Jessica, James, Danelle F., Clow, Fong, Styles, Lori, Valentino, Rudy, Wildgust, Mark, Mahler, Michelle and Burger, Jan A. (2017). Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica, 102 (10). S. 1796 - 1806. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Kipps, Thomas J., Fraser, Graeme, Coutre, Steven E., Brown, Jennifer R., Barrientos, Jacqueline C., Barr, Paul M., Byrd, John C., O'Brien, Susan M., Dilhuydy, Marie-Sarah, Hillmen, Peter, Jaeger, Ulrich, Moreno, Carol, Cramer, Paula, Stilgenbauer, Stephan, Chanan-Khan, Asher A., Mahler, Michelle, Salman, Mariya, Eckert, Karl, Solman, Isabelle G., Balasubramanian, Sriram, Cheng, Mei, Londhe, Anil, Ninomoto, Joi, Howes, Angela, James, Danelle F. and Hallek, Michael (2019). Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. Clin. Lymphoma Myeloma Leuk., 19 (11). S. 715 - 729. DALLAS: CIG MEDIA GROUP, LP. ISSN 2152-2669

Kipps, Thomas J., Hillmen, Peter, Demirkan, Fatih ORCID: 0000-0002-1172-8668, Grosicki, Sebastian, Coutre, Steven E., Barrientos, Jacqueline C., Barr, Paul M., Janssens, Ann, Byrd, John C., O'Brien, Susan M., Fraser, Graeme, Jaeger, Ulrich, Cramer, Paula, Stilgenbauer, Stephan, Chanan-Khan, Asher A., Salman, Mariya, Solman, Isabelle, Cheng, Mei, Phelps, Charles, Ninomoto, Joi, Howes, Angela, James, Danelle F. and Hallek, Michael (2016). 11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies. Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

O'Brien, Susan, Hillmen, Peter ORCID: 0000-0001-5617-4403, Coutre, Steven, Barr, Paul M., Fraser, Graeme, Tedeschi, Alessandra, Burger, Jan A., Dilhuydy, Marie-Sarah, Hess, Georg, Moreno, Carol, Cramer, Paula, Liu, Emily, Chang, Stephen, Vermeulen, Jessica, Styles, Lori, Howes, Angela, James, Danelle F., Patel, Kalpesh, Graef, Thorsten and Valentino, Rudolph (2018). Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. Clin. Lymphoma Myeloma Leuk., 18 (10). S. 648 - 673. DALLAS: CIG MEDIA GROUP, LP. ISSN 2152-2669

O'Brien, Susan, Jones, Jeffrey A., Coutre, Steven, Mato, Anthony R., Hillmen, Peter, Tam, Constantine, Osterborg, Anders, Siddiqi, Tanya, Thirman, Michael J., Furman, Richard R., Ilhan, Osman, Keating, Michael, Call, Timothy G., Brown, Jennifer R., Stevens-Brogan, Michelle, Li, Yunfeng, Fardis, Maria, Clow, Fong, James, Danelle F., Chu, Alvina D., Hallek, Michael and Stilgenbauer, Stephan (2014). Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results from the Phase II RESONATE (TM)-17 Trial. Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

O'Brien, Susan, Jones, Jeffrey A., Coutre, Steven E., Mato, Anthony R., Hillmen, Peter, Tam, Constantine ORCID: 0000-0002-9759-5017, Osterborg, Anders, Siddiqi, Tanya ORCID: 0000-0001-5292-8298, Thirman, Michael J., Furman, Richard R., Ilhan, Osman, Keating, Michael J., Call, Timothy G., Brown, Jennifer R., Stevens-Brogan, Michelle, Li, Yunfeng, Clow, Fong, James, Danelle F., Chu, Alvina D., Hallek, Michael and Stilgenbauer, Stephan (2016). Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol., 17 (10). S. 1409 - 1419. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Stilgenbauer, Stephan, Jones, Jeffrey A., Coutre, Steven, Mato, Anthony R., Hillmen, Peter, Tam, Constantine, Osterborg, Anders, Siddiqi, Tanya, Thirman, Michael J., Furman, Richard R., Ilhan, Osman, Keating, Michael, Call, Timothy G., Brown, Jennifer R., Li, Yunfeng, Eckert, Karl, Chang, Betty Y., James, Danelle F., Chu, Alvina D., Hallek, Michael and O'Brien, Susan (2015). Outcome of Ibrutinib Treatment by Baseline Genetic Features in Patients with Relapsed or Refractory CLL/SLL with del17p in the Resonate-17 Study. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

This list was generated on Thu Apr 18 08:25:45 2024 CEST.